AOD-9604 vs Semaglutide: A Research Peptide vs an FDA-Approved Medication

Key takeaways:

• Semaglutide is FDA-approved for weight management with extensive clinical trial data showing 14.9% average weight loss
• AOD-9604 is a research peptide that is NOT FDA-approved for any indication and has very limited human clinical data
• They work through completely different mechanisms -- semaglutide targets GLP-1 receptors (appetite suppression), AOD-9604 is a modified growth hormone fragment (lipolysis)
• The evidence gap between these two compounds is massive -- semaglutide has thousands of participants across multiple Phase 3 trials, AOD-9604 has small early-phase studies
• AOD-9604 appeals to people seeking non-GLP-1 options, but the lack of robust human data means outcomes are far less predictable

Important: This article is for educational and informational purposes only. It is not medical advice. AOD-9604 is a research compound not approved by the FDA for weight loss or any other indication. Always consult a qualified healthcare provider before considering any peptide or medication. See our full medical disclaimer.

Two fundamentally different compounds

Comparing AOD-9604 to semaglutide is not like comparing two GLP-1 medications. These are entirely different classes of compounds with different mechanisms, different levels of evidence, and different regulatory statuses.

Think of it this way: semaglutide is a well-studied, FDA-approved medication backed by trials involving tens of thousands of participants. AOD-9604 is a research peptide with a handful of small studies and no regulatory approval for weight management anywhere in the world (except as a food supplement in Australia, which is a different regulatory category).

That does not mean AOD-9604 is worthless. It means the comparison requires honesty about where each compound actually stands in terms of evidence.

How semaglutide works

Semaglutide is a GLP-1 receptor agonist. It mimics the incretin hormone GLP-1, which your body produces naturally after eating. By activating GLP-1 receptors in the brain and gut, semaglutide reduces appetite, slows gastric emptying, and improves insulin sensitivity.

The STEP 1 trial demonstrated that semaglutide 2.4mg (Wegovy) produced an average of 14.9% body weight loss over 68 weeks in adults with obesity (PMID: 33567185). That trial enrolled 1,961 participants and was randomized, double-blind, and placebo-controlled -- the gold standard for clinical evidence.

The weight loss effect is primarily driven by appetite reduction. People on semaglutide eat less because they feel full sooner and think about food less frequently. There is also emerging evidence of direct effects on body composition, though muscle loss remains a concern (see our GLP-1 muscle loss guide for more on this).

How AOD-9604 works

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide fragment of human growth hormone. Specifically, it corresponds to the C-terminal fragment of hGH (amino acids 177-191) with a tyrosine modification.

The theory behind AOD-9604 is straightforward: growth hormone has fat-burning properties, but full-length hGH also causes unwanted effects like insulin resistance, water retention, and potential tumor growth. AOD-9604 was designed to isolate the lipolytic (fat-burning) portion of the growth hormone molecule without the metabolic downsides.

Early research suggested that AOD-9604 stimulates lipolysis (the breakdown of stored fat) and inhibits lipogenesis (the creation of new fat) without affecting blood sugar or growth patterns (PMID: 11713870).

The mechanism is entirely different from semaglutide. AOD-9604 does not reduce appetite. It does not slow gastric emptying. It does not affect GLP-1 signaling. It works directly on fat tissue -- at least in the lab.

The evidence gap

This is where the comparison gets uncomfortable for AOD-9604 proponents.

Semaglutide's evidence base:

• Multiple Phase 3 clinical trials (STEP program) with thousands of participants
• FDA-approved for chronic weight management (Wegovy, 2.4mg weekly injection)
• FDA-approved for type 2 diabetes (Ozempic, up to 2mg weekly)
• Published in top-tier journals (NEJM, Lancet, JAMA)
• Long-term safety data extending beyond 2 years
• Head-to-head comparison data against other GLP-1s

AOD-9604's evidence base:

• Animal studies showing fat reduction in obese mice and rats
• A small Phase 2 clinical trial that did not meet its primary endpoint for statistically significant weight loss
• Classified as a food supplement (not a drug) by Australian regulatory authorities (TGA)
• No FDA approval for any indication
• No published Phase 3 clinical trial data
• No long-term human safety data

The Phase 2 trial of oral AOD-9604 in overweight adults showed modest body weight reductions, but the results were not statistically significant compared to placebo across all dose groups. This is a critical point that often gets lost in online discussions about the peptide.

Weight loss comparison

Putting numbers side by side requires a caveat: the data quality is not comparable.

Metric	Semaglutide 2.4mg	AOD-9604
Average weight loss	14.9% (68 weeks)	Not established with statistical significance
Trial size	1,961 participants (STEP 1)	Small Phase 2 (exact protocol varies by study)
Trial quality	Phase 3, randomized, double-blind	Phase 2, limited enrollment
FDA status	Approved (Wegovy)	Not approved
Mechanism	Appetite suppression (GLP-1)	Lipolysis stimulation (hGH fragment)
Muscle preservation	Concern -- some lean mass loss	Limited data -- theoretical preservation

Source: STEP 1 (PMID: 33567185), AOD-9604 mechanism (PMID: 11713870)

Anecdotal reports from individuals using AOD-9604 (typically via subcutaneous injection from compounding pharmacies or research peptide suppliers) describe modest fat reduction, particularly when combined with exercise and calorie management. But anecdotal reports are not clinical evidence, and the placebo effect combined with lifestyle changes can account for a lot.

Side effects comparison

Semaglutide's side effects are well-documented thanks to large-scale trials. GI symptoms are the most common -- nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%) in the STEP 1 trial.

More serious but rare risks include pancreatitis, gallbladder disease, and a boxed warning for medullary thyroid carcinoma risk based on animal studies. Semaglutide also carries concerns about lean muscle mass loss during rapid weight reduction.

AOD-9604's side effect profile is less defined due to limited clinical data. The available research suggests it does not cause the metabolic disruptions associated with full-length growth hormone -- no significant changes in blood glucose, IGF-1 levels, or cortisol. In the small clinical studies that exist, it appeared well-tolerated.

However, "limited data showing few side effects" is not the same as "proven safe." It may simply mean we have not studied it enough to identify the risks.

Cost and availability

Factor	Semaglutide (Wegovy)	AOD-9604
Monthly cost	$1,000-1,300 (brand)	$100-300 (research peptide)
Insurance coverage	Possible (varies by plan)	Not covered
Prescription required	Yes	Varies by source
Quality control	FDA-regulated manufacturing	Variable -- depends on supplier
Legal status	FDA-approved prescription drug	Gray market in the US

The cost difference is significant, and it is one of the primary reasons people seek out AOD-9604. But lower cost comes with tradeoffs in quality assurance, purity verification, and legal clarity. Research peptides purchased online are not subject to the same manufacturing standards as FDA-approved medications.

Who considers AOD-9604 and why

Despite the evidence gap, AOD-9604 has a loyal following. The typical profile of someone interested in AOD-9604:

• GLP-1 intolerant: Tried semaglutide or tirzepatide and could not tolerate the GI side effects
• Needle-averse but peptide-curious: Looking for alternatives to GLP-1 injections (though AOD-9604 is also typically injected)
• Body composition focused: Interested in fat loss specifically without the appetite suppression mechanism
• Cost-sensitive: Cannot afford or access GLP-1 medications at $1,000+/month
• Philosophically opposed to GLP-1s: Prefer not to alter appetite signaling

These are understandable motivations. But wanting an alternative does not make the alternative equally effective.

The honest assessment

If you are choosing between AOD-9604 and semaglutide based purely on evidence, semaglutide is not close to a contest. It has dramatically more data, FDA approval, defined dosing protocols, and predictable outcomes.

AOD-9604 is a research peptide with an interesting mechanism and a theoretical rationale for fat reduction, but the clinical evidence to support its use for weight loss in humans is thin. The Phase 2 data was not strong enough to advance to Phase 3 trials, which tells you something about how the pharmaceutical companies that developed it assessed its commercial potential.

That said, the peptide research landscape is evolving. For updates on what is coming next in weight loss peptides, see our coverage of retatrutide and survodutide, both of which are further along in clinical development.

For a comparison of the leading FDA-approved options, see our semaglutide vs tirzepatide breakdown.

Sources

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
2. Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology. 2001;142(12):5182-9. PMID: 11713870

---

This article is for educational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. See our full medical disclaimer.